Back to top
more

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$14.74 USD

14.74
2,889,678

-0.16 (-1.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Immunomedics' Shares Rise on Positive Breast Cancer Drug Data

Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.

Immunomedics' Shares Surge YTD on Cancer Drug Approval

Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.

Immunomedics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Immunomedics.

Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Why Is Immunomedics (IMMU) Down 6.6% Since Last Earnings Report?

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Is Immunomedics (IMMU) Stock Outpacing Its Medical Peers This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.

Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q1 revenues increase year over year.

Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus

Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.

Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Immunomedics, Inc. (IMMU) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Immunomedics, Inc. (IMMU).

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Why Immunomedics (IMMU) Might Surprise This Earnings Season

Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Hanger (HNGR) to Report Q1 Earnings: What's in the Cards?

Hanger's (HNGR) first-quarter 2020 results are likely to reflect strong performance at its Patient Care segment, partially offset by high costs.

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Sweta Killa headshot

First-Mover Pandemic Disease Fight ETF On The Way

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Immunomedics Wins Fast FDA Approval for Breast Cancer Drug

The FDA nods to Immunomedics' (IMMU) Trodelvy for treating patients with metastatic triple-negative breast cancer, having previously received minimum two therapies. Stock rallies in pre-market trading.

Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC

The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).